Literature DB >> 25019157

ACE and ACE2 in inflammation: a tale of two enzymes.

Ravinder Reddy Gaddam, Stephen Chambers, Madhav Bhatia1.   

Abstract

The renin-angiotensin system (RAS) conceived as a coordinated hormonal cascade plays an important role in controlling multiple functions in many organs and is much more complex than previously thought. The RAS has continued to expand, with the identification of new components, functions and subsystems. Angiotensin-converting enzyme (ACE) and its novel homolog angiotensin converting enzyme 2 (ACE2) are two key enzymes involved in the synthesis of bioactive components of the RAS. The main active peptides of the RAS include angiotensin II (Ang II), Ang III, Ang IV, and angiotensin-(1-7) [Ang-(1-7)] among which Ang II and Ang-(1-7) are much more important in health and disease. The axis formed by ACE2 represents an endogenous counter-regulatory pathway within the RAS, and its actions are opposite to those of the ACE axis. Conventionally the RAS has been considered to be important in the cardiovascular system, metabolism, cell growth and homeostasis. In recent years, a key role of ACE and ACE2 and their peptides has been recognized in the inflammatory process in conditions such as cardiac hypertrophy, pulmonary hypertension, glomerulonephritis, lung injury, sepsis, and acute pancreatitis. Investigations are ongoing to better understand the role of the RAS in inflammation. A comprehensive understanding of the RAS components in inflammation can provide new possibilities for therapeutic approaches against inflammatory diseases. In this review, we discuss our current understanding of the subject, based on recent findings, on the role of ACE and ACE2 in inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25019157     DOI: 10.2174/1871528113666140713164506

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  59 in total

Review 1.  The Angiotensin-converting Enzyme Insertion/Deletion Polymorphism as a Common Risk Factor for Major Pregnancy Complications.

Authors:  Christos Yapijakis; Iphigenia Gintoni; Maria Adamopoulou
Journal:  In Vivo       Date:  2021 Jan-Feb       Impact factor: 2.155

Review 2.  Neuroprotective mechanisms of the ACE2-angiotensin-(1-7)-Mas axis in stroke.

Authors:  Douglas M Bennion; Emily Haltigan; Robert W Regenhardt; U Muscha Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2015-02       Impact factor: 5.369

3.  A Dynamic Variation of Pulmonary ACE2 Is Required to Modulate Neutrophilic Inflammation in Response to Pseudomonas aeruginosa Lung Infection in Mice.

Authors:  Chhinder P Sodhi; Jenny Nguyen; Yukihiro Yamaguchi; Adam D Werts; Peng Lu; Mitchell R Ladd; William B Fulton; Mark L Kovler; Sanxia Wang; Thomas Prindle; Yong Zhang; Eric D Lazartigues; Michael J Holtzman; John F Alcorn; David J Hackam; Hongpeng Jia
Journal:  J Immunol       Date:  2019-10-23       Impact factor: 5.422

4.  Molecular and cellular mechanisms of the inhibitory effects of ACE-2/ANG1-7/Mas axis on lung injury.

Authors:  Indiwari Gopallawa; Bruce D Uhal
Journal:  Curr Top Pharmacol       Date:  2014-01-01

5.  Dose-dependent, therapeutic potential of angiotensin-(1-7) for the treatment of pulmonary arterial hypertension.

Authors:  Siegfried Breitling; Adrienn Krauszman; Richa Parihar; Thomas Walther; Mark K Friedberg; Wolfgang M Kuebler
Journal:  Pulm Circ       Date:  2015-12       Impact factor: 3.017

Review 6.  The Impact of ACE and ACE2 Gene Polymorphisms in Pulmonary Diseases Including COVID-19.

Authors:  Iphigenia Gintoni; Maria Adamopoulou; Christos Yapijakis
Journal:  In Vivo       Date:  2022 Jan-Feb       Impact factor: 2.155

Review 7.  Addressing the Symptoms or Fixing the Problem? Developing Countermeasures against Normal Tissue Radiation Injury.

Authors:  Jacqueline P Williams; Laura Calvi; Joe V Chakkalakal; Jacob N Finkelstein; M Kerry O'Banion; Edward Puzas
Journal:  Radiat Res       Date:  2016-06-22       Impact factor: 2.841

8.  Angiotensin-converting enzyme 2 inhibits high-mobility group box 1 and attenuates cardiac dysfunction post-myocardial ischemia.

Authors:  Yan Fei Qi; Juan Zhang; Lei Wang; Vinayak Shenoy; Eric Krause; S Paul Oh; Carl J Pepine; Michael J Katovich; Mohan K Raizada
Journal:  J Mol Med (Berl)       Date:  2016-01       Impact factor: 4.599

9.  Can laboratory findings predict pulmonary involvement in children with COVID-19 infection?

Authors:  Elif Böncüoğlu; Mehmet Coşkun; Elif Kıymet; Tülay Öztürk Atasoy; Şahika Şahinkaya; Ela Cem; Mine Düzgöl; Miray Yılmaz Çelebi; Aybüke Akaslan Kara; Kamile Ö Arıkan; Nuri Bayram; İlker Devrim
Journal:  Pediatr Pulmonol       Date:  2021-05-13

Review 10.  Receptor for advanced glycation end-products axis and coronavirus disease 2019 in inflammatory bowel diseases: A dangerous liaison?

Authors:  Armando Rojas; Iván Schneider; Cristian Lindner; Ileana Gonzàlez; Miguel Angel Morales
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.